NSA is supporting Moredun's work to find a vaccine for Louping Ill
Moredun Research Institute has developed a next-generation vaccine against Louping Ill virus (LIV) in sheep. The vaccine has been highly effective in research trials. They are now partnering with Kernfarm to bring it to market, to make it available to UK sheep farmers in high-need areas.
Louping Ill is a tick-borne viral disease that affects multiple species, including sheep and red grouse, and occasionally cattle, horses, dogs, and humans. The tick-borne disease can have a high mortality rate in sheep and red grouse, of up to 50% and 80% respectively, when the virus is first encountered.
The previous LIV vaccine was withdrawn in 2017 and no alternative is currently available. Given the recent trend of longer tick seasons and the subsequent increasing spread of the disease, this new vaccine has been welcomed by livestock farmers, vets and the moorland industry. Importantly, the new vaccine is simpler to manufacture, ensuring a more reliable supply for farmers.
Since the usual pharmaceutical route was not possible due to the niche UK market, industry funding is required for Louping Ill vaccine development commercialisation. Moredun is initially seeking £720,000 to complete Phase 1 of this project.
Donations can be made online or via bank transfer.
Every donation counts.
No matter the size, your support helps us get one step closer to making this vaccine a reality - and we are truly grateful.
